EICHOR
● Recruiting
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
Condition: Atopic Dermatitis · Sponsor: Chong Kun Dang Pharmaceutical
About this study
This is a randomised, double-blind, three-arm, parallel group, single-dose, Phase 1 comparative study of CKD-706, US-Dupixent, and EU-Dupixent in healthy adult participants.
This description comes directly from the study's public registry record.
Talk to the study team
Camilla Rincon · +49 30 306851306 · camila.rincon@parexel.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Parexel EPCU Berlin | Berlin, State of Berlin, Germany | Not Yet Recruiting |
| Parexel EPCU London | London, England, United Kingdom | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07358156